RLAYRelay Therapeutics, Inc.Signing up patients
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
PIK3CA Mutation · HER2- Negative Breast Cancer · Hormone Receptor Positive Tumor · Breast Cancer · Metastatic Breast Cancer · Advanced Breast Cancer
9Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +9
3 insiders sold shares within a month
Since Oct 28, 2026 · was worth 10, fading over time
Worry score9
Score over time
- Stage
- Phase 3
- Patients
- 540 (planned)
- Started
- Aug 26, 2025
- Main results expected
- Apr 30, 2028
- Fully finished
- Dec 31, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS) within the overall and kinase population by blinded independent central review (BICR)
Measured over: The time from date of randomization until radiographic progression per RECIST v1.1, or death due to any cause, up to approximately 77 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 10, now 9, since 2026-10-28, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06982521 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC